Sahin IH, Saridogan T, Ayasun R, et al. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. JCO Oncol Pract 2024;20(10):1336-1347.
DOI: 10.1200/OP.23.00787
Henry JT, Coker O, Chowdjury S, et al. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol 2021;5:613-621.
DOI: 10.1200/PO.20.00256
Schirripa M, Nappo F, Cremolini C, et al. KRAS G12C metastatic colorectal cancer: Specific features of a new emerging target population. Clin Colorectal Cancer Clin Colorectal Cancer 2020;19(3):219-225.
DOI: 10.1016/j.clcc.2020.04.009
Lanman BA, Allen JR, Allen JG, et al. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. J Med Chem 2020;63(1):52-65.
DOI: 10.1021/acs.jmedchem.9b01180
Chen H, Smaill JB, Liu T, et al. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. J Med Chem 2020;63(23):14404-14424.
DOI: 10.1021/acs.jmedchem.0c01312
Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019;575(7781):217-223.
DOI: 10.1038/s41586-019-1694-1
Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov 2020;10:54–71.
DOI: 10.1158/2159-8290.CD-19-1167
Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med 2022;387:120–31.
DOI: 10.1056/NEJMoa2204619
Ou SI, Jänne PA, Leal TA, et al. Firstin-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1).J Clin Oncol 2022;40:2530–8.
DOI: 10.1200/JCO.21.02752
Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov 2020;10:1129–39.
DOI: 10.1158/2159-8290.CD-20-0187
Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23: 115-124.
DOI: 10.1016/S1470-2045(21)00605-7
Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023;389:2125-39.
DOI: 10.1056/NEJMoa2308795
Pietrantonio F, Salvatore L, Esaki T, et al. Overall Survival Analysis of the Phase III CodeBreaK300 Study of Sotorasib Plus Panitumumab Versus Investigator’s Choice in Chemorefractory KRAS G12C. Colorectal Cancer. J Clin Oncol 2025; 43(19):2147-2154.
DOI: 10.1200/JCO-24-02026
Salvatore L, Katlinskaya Y, Anderson A, et al. Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12Cmutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study. J Clin Oncol 2025;43(16 suppl).
DOI: 10.1200/JCO.2025.43.16_suppl.3540
Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med 2024:1-6.
DOI: 10.1038/s41591-023-02717-6
Strickler JH, Kuboki Y, Hong DS, et al. Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b). J Clin Oncol 2025;43(16 suppl):3506-3506.
DOI: 10.1200/JCO.2025.43.16_suppl.3506
Kim TW, Price T, Grasselli J, et al. A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). J Clin Oncol 2025;43(4 suppl).
DOI: 10.1200/JCO.2025.43.4_suppl.TPS326
Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023;388:44-54.
DOI: 10.1056/NEJMoa2212419
Yaeger R, Uboha NV, Klempner SJ, et al. Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1. J Clin Oncol 2025;43(131 suppl).
DOI: 10.1200/JCO.2025.43.4_suppl.131
Fernández Montes A, Alonso V, Aranda Aguilar E, et al. 2025 Updated version v1.0 SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). Clin Transl Oncol 2025.27(4):1845–1850.
L. Candia , A. Cervantes & E. Martinelli4 , on behalf of the ESMO Guidelines Committee. Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol 2025; 36(3): 342-44
DOI: 10.1016/j.annonc.2024.11.015
Ruan D-Y, Wu H-X, Cu Y, et al. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Sig Transduct Target Ther 2025;10:189.
DOI: 10.1038/s41392-025-02274-z
Hollebecque A, Koyama T, Fujiwara Y, et al. Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer. J Clin Oncol 2025; 43(16 suppl):3507.
DOI: 10.1200/JCO.2025.43.16_suppl.3507
Li J, Huang J, Ba Y, et al. Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer. J Clin Oncol 2025; 43(4 suppl):191
DOI: 10.1200/JCO.2025.43.4_suppl.191
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954.
DOI: 10.1038/nature00766
Levin-Sparenberg E, Bylsma LC, Lowe K, Sangaré L, Fryzek JP, Alexander DD. A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer. Gastroenterology Res. 2020;13(5):184–198.
DOI: 10.14740/gr1167
Clarke CN and Kopetz ES. BRAF mutantcolorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 2015; 6: 660–667.
Rowland A, Lee S, et al.BRAF mutations and survival in colorectal cancer: a systematic review and meta-analysis. Annals of Oncology. 2015;26(7):1315–1327.PMID: 25979453 •
Yaeger R, Yao Z, Hyman DM, et al.Distinct clinical and biological characteristics of colorectal cancers with BRAF non-V600mutations.Cancer.2019;125(4):575–582.PMID: 30311651
Barras D, Missiaglia E, Wirapati P, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 2017; 23: 104–115.
DOI: 10.1158/1078-0432.CCR-16-0140
Jones JC, Renfro LA, Al-Shamsi HO, et al. Non- V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol 2017; 35: 2624–2630.
DOI: 10.1200/JCO.2016.71.4394
Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888–1894.
DOI: 10.1038/bjc.2015.173
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroupanalyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306–1315.
DOI: 10.1016/S1470-2045(15)00122-9
Cremolini C, Loupakis F, Antoniotti C, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(5):497 507.
DOI: 10.1016/S1470-2045(19)30862-9
Kopetz S, Desai J, Chan E, et al. A Phase I/II study of vemurafenib in patients with metastatic colorectal cancer harboring the BRAF V600E mutation. J Clin Oncol. 2015;33(34):4032–4038.
DOI: 10.1200/JCO.2015.63.2497
Corcoran RB, Ebi H, Turke AB, et al. EGFR mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Research. 2012;72(24):
DOI: 10.1158/1538-7445.AM2012-LB-350
Kopetz S, Corcoran RB, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAF^V600E Mutant Colorectal Cancer. Cancer Discovery. 2018;8(4):428–443.
DOI: 10.1158/2159-8290.CD-17-1226
Kopetz S, Desai J, Chan E, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2020;38(4):354 363.
Corcoran RB, Grothey A, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E mutant colorectal cancer. Cancer Discovery. 2018;8(4):428 443.
DOI: 10.1158/2159-8290.CD-17-1226
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632–1643.
DOI: 10.1056/NEJMoa1908075
Tabernero J. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2021;39(22):2389–2398.
Van Cutsem, E. et al. ANCHOR CRC: results from a single-arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreated BRAF^V600E–mutant metastatic colorectal cancer. J Clin Oncol. 2023; 41(14):2628-2637.
DOI: 10.1200/JCO.22.01693
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberté R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators; Poulsen LØ. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N Engl J Med. 2025;392(24):2425–2437.
DOI: 10.1056/NEJMoa2501912
Kopetz S, Grothey A, Elez E, et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial (BREAKWATER). Nat Med. 2025;31(3):901–908.
DOI: 10.1038/s41591-024-03443-3
André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al.
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer.
New England Journal of Medicine. 2020;383:2207–2218.
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al.
Nivolumab in patients with metastatic DNA mismatch repair–deficient or microsatellite instability–high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet Oncology. 2017;18(9):1182–1191.
DOI: 10.1016/S1470-2045(17)30422-9
Morris VK, Guthrie KA, Kopetz S, Breakstone R, Karasic T, Hu ZI, Colby S, Fakih M, Gholami S, Gold PJ, Philip PA. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer: SWOG S2107. J Clin Oncol. 2023;41(suppl 4):TPS265.
DOI: 10.1200/JCO.2023.41.4_suppl.TPS265
Yaeger R, Chatila WK, Lipsyc-Sharf M, et al.
“RNF43 mutations predict response to combined BRAF and EGFR inhibition in BRAF-V600E metastatic colorectal cancer.” Nature Medicine. 2022;28:2172–2181.
Matsubara Y, et al. BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E–mutant metastatic colorectal cancer. J Clin Oncol. 2023;41(4_suppl):TPS271.
DOI: 10.1200/JCO.2023.41.4_suppl.TPS271
Phase II Study of ctDNA guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET), Clinical Trial ID NCT06578559.
Kotani D, et al. TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib and cetuximab in patients with RAS wild type / BRAF V600E–mutant metastatic colorectal cancer. J Clin Oncol. 2023;41(4_suppl): TPS264
DOI: 10.1200/JCO.2023.41.4_suppl.TPS264
Número de descargas:
375
Número de visitas:
35
Citas:
0
